EP2825048A4 - Cellules précurseurs d'érythrocyte modifiées et leurs utilisations - Google Patents

Cellules précurseurs d'érythrocyte modifiées et leurs utilisations

Info

Publication number
EP2825048A4
EP2825048A4 EP13760391.6A EP13760391A EP2825048A4 EP 2825048 A4 EP2825048 A4 EP 2825048A4 EP 13760391 A EP13760391 A EP 13760391A EP 2825048 A4 EP2825048 A4 EP 2825048A4
Authority
EP
European Patent Office
Prior art keywords
precursor cells
erythrocyte precursor
modified erythrocyte
modified
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13760391.6A
Other languages
German (de)
English (en)
Other versions
EP2825048A1 (fr
Inventor
James W Edinger
Stewart Abbot
Bitao Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clarity Acquisition II LLC
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Priority to EP17183779.2A priority Critical patent/EP3295945A1/fr
Priority to EP22161046.2A priority patent/EP4052717A1/fr
Publication of EP2825048A1 publication Critical patent/EP2825048A1/fr
Publication of EP2825048A4 publication Critical patent/EP2825048A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
EP13760391.6A 2012-03-13 2013-03-12 Cellules précurseurs d'érythrocyte modifiées et leurs utilisations Withdrawn EP2825048A4 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP17183779.2A EP3295945A1 (fr) 2012-03-13 2013-03-12 Cellules de précurseur d'érythrocytes modifiées et leurs utilisations
EP22161046.2A EP4052717A1 (fr) 2012-03-13 2013-03-12 Cellules de précurseur d'érythrocytes modifiées et leurs utilisations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610355P 2012-03-13 2012-03-13
US201261611402P 2012-03-15 2012-03-15
PCT/US2013/030463 WO2013138314A1 (fr) 2012-03-13 2013-03-12 Cellules précurseurs d'érythrocyte modifiées et leurs utilisations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP17183779.2A Division EP3295945A1 (fr) 2012-03-13 2013-03-12 Cellules de précurseur d'érythrocytes modifiées et leurs utilisations
EP22161046.2A Division EP4052717A1 (fr) 2012-03-13 2013-03-12 Cellules de précurseur d'érythrocytes modifiées et leurs utilisations

Publications (2)

Publication Number Publication Date
EP2825048A1 EP2825048A1 (fr) 2015-01-21
EP2825048A4 true EP2825048A4 (fr) 2015-10-14

Family

ID=49161718

Family Applications (3)

Application Number Title Priority Date Filing Date
EP17183779.2A Withdrawn EP3295945A1 (fr) 2012-03-13 2013-03-12 Cellules de précurseur d'érythrocytes modifiées et leurs utilisations
EP22161046.2A Withdrawn EP4052717A1 (fr) 2012-03-13 2013-03-12 Cellules de précurseur d'érythrocytes modifiées et leurs utilisations
EP13760391.6A Withdrawn EP2825048A4 (fr) 2012-03-13 2013-03-12 Cellules précurseurs d'érythrocyte modifiées et leurs utilisations

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP17183779.2A Withdrawn EP3295945A1 (fr) 2012-03-13 2013-03-12 Cellules de précurseur d'érythrocytes modifiées et leurs utilisations
EP22161046.2A Withdrawn EP4052717A1 (fr) 2012-03-13 2013-03-12 Cellules de précurseur d'érythrocytes modifiées et leurs utilisations

Country Status (5)

Country Link
US (1) US20150118265A1 (fr)
EP (3) EP3295945A1 (fr)
AU (1) AU2013203832B2 (fr)
HK (2) HK1206201A1 (fr)
WO (1) WO2013138314A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2930665A1 (fr) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Complexes membrane synthetique- recepteur
MA39819A (fr) 2014-04-01 2017-02-08 Rubius Therapeutics Inc Méthodes et compositions d'immunomodulation
SI3402491T1 (sl) 2016-01-11 2022-05-31 Rubius Therapeutics, Inc. Sestavki in postopki v zvezi z multimodalnimi terapevtskimi celičnimi sistemi za indikacije raka
CN110520522A (zh) 2017-02-17 2019-11-29 鲁比厄斯治疗法股份有限公司 功能化红系细胞
CN110357968B (zh) * 2018-04-08 2023-08-25 吉林省汇融生物科技有限公司 抗肿瘤融合蛋白及其制法和应用
CN112852741A (zh) * 2019-11-28 2021-05-28 华东师范大学 一种嵌合抗原受体t细胞及其制备方法和细胞药物
EP3881864A1 (fr) * 2020-03-20 2021-09-22 Sanquin Innovatie B.V. Vaccins induisant une glycosylation améliorée d'anticorps igg

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029183A2 (fr) * 1996-02-08 1997-08-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procedes et compositions pour transformer des cellules dendritiques et activer des lymphocytes t

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US7767202B2 (en) * 2001-03-16 2010-08-03 The Johns Hopkins University Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules
DE60333487D1 (de) * 2002-12-13 2010-09-02 Genetix Pharmaceuticals Inc Therapeutische retrovirus-vektoren für gentherapie
US8211656B2 (en) * 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
EP2419511B1 (fr) * 2009-04-09 2018-01-17 Sangamo Therapeutics, Inc. Intégration ciblée dans des cellules souches
US8586360B2 (en) 2009-07-02 2013-11-19 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029183A2 (fr) * 1996-02-08 1997-08-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procedes et compositions pour transformer des cellules dendritiques et activer des lymphocytes t

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DOMINICI S ET AL: "Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL", VACCINE, ELSEVIER LTD, GB, vol. 21, no. 17-18, 16 May 2003 (2003-05-16), pages 2082 - 2090, XP004421124, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(02)00745-4 *
GIARRATANA M-C ET AL: "Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, US, vol. 23, no. 1, 1 January 2005 (2005-01-01), pages 69 - 74, XP002334363, ISSN: 1087-0156, DOI: 10.1038/NBT1047 *

Also Published As

Publication number Publication date
HK1206201A1 (en) 2016-01-08
US20150118265A1 (en) 2015-04-30
WO2013138314A1 (fr) 2013-09-19
AU2013203832B2 (en) 2016-09-15
EP4052717A1 (fr) 2022-09-07
EP2825048A1 (fr) 2015-01-21
AU2013203832A1 (en) 2013-10-03
EP3295945A1 (fr) 2018-03-21
HK1252801A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
FR25C1018I2 (fr) Éthers d'aryle et leurs utilisations
EP2882847A4 (fr) Cellules tueuses naturelles et leurs utilisations
EP2802647A4 (fr) Cellules progénitrices de poumon humain isolé et leurs utilisations
EP2794654A4 (fr) Anticorps anti-phf-tau et leurs utilisations
EP2885318A4 (fr) Conjugués peptides-dendrimères et leurs utilisations
PL2928923T3 (pl) Przeciwciała przeciwko antygenowi 2 komórek dendrytycznych krwi i ich zastosowania
EP2861622A4 (fr) Anticorps anti-idiotypiques anti-cd22 et leurs utilisations
EP2841458A4 (fr) Régions modifiées d'anticorps et leurs utilisations
EP2914622C0 (fr) Nouvelles molécules de fusion et leurs utilisations
EP2825200A4 (fr) Anticorps anti-cd27 humains, leurs procédés et leurs utilisations
EP2600878A4 (fr) Lymphocytes b régulateurs et leurs utilisations
EP2683406A4 (fr) Anticorps anti-cd40 et leurs utilisations
EP2718325A4 (fr) Anticorps anti-psgl-1 et leurs utilisations
EP2822936A4 (fr) Dérivés d'aminoquinoléine et leurs utilisations
EP2710124A4 (fr) Cellules progénitrices neuronales et utilisations
EP2714023A4 (fr) Nano-ensembles polymères réticulés et leurs utilisations
EP2621955A4 (fr) Anticorps anti-ceacam6 et leurs utilisations
EP2875014A4 (fr) Médicaments anti-mucus et leurs utilisations
EP2718326A4 (fr) Anticorps contre g-csfr et leurs utilisations
EP2726103A4 (fr) Anticorps anti-properdine et leurs utilisations
EP2608785A4 (fr) Lipomacrocycles et leurs utilisations
EP2678017A4 (fr) Urées asymétriques et utilisations médicales de celles-ci
DK3901251T3 (da) Nyrecellepopulationer og anvendelse heraf
EP2807160A4 (fr) Composés antifibrotiques et leurs utilisations
EP2683360A4 (fr) Apeline pégylée et ses utilisations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140930

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150914

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/078 20100101ALI20150908BHEP

Ipc: A61K 39/00 20060101ALI20150908BHEP

Ipc: A61K 39/12 20060101ALI20150908BHEP

Ipc: A61K 39/02 20060101ALI20150908BHEP

Ipc: A61K 35/18 20150101AFI20150908BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1206201

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170729

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1206201

Country of ref document: HK